TIL therapy and anti-CTLA4: can they co-exist?

Forget, Marie-Andrée; Haymaker, Cara; Amaria, Rodabe N; Bernatchez, Chantale

Forget, Marie-Andrée; Haymaker, Cara; Amaria, Rodabe N; Bernatchez, Chantale.

Afiliación

Forget MA; Chantale Bernatchez: Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, TX, USA.
Haymaker C; Rodabe N. Amaria: Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX, USA.
Amaria RN; Chantale Bernatchez: Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, TX, USA.
Bernatchez C; Rodabe N. Amaria: Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX, USA.

Oncotarget ; 10(1): 1-2, 2019 Jan 01.

Article en En | MEDLINE | ID: mdl-30713594

Palabras clave

CTLA4; TIL; metastatic melanoma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google